SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
November 12 2020 - 4:05PM
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage
pharmaceutical company focused on the health security market, today
announced that Dr. Dennis Hruby, Chief Scientific Officer, will
participate in a panel discussion at the Non-Conventional Threats
(NCT) Asia Virtual Conference.
The panel discussion titled, “COVID-19: Insights
on an Epidemic Outbreak” will take place at 12:00 p.m. Malaysia
Time on Friday, November 13, 2020 with Dr. Hruby speaking as one
member of the panel at the conference.
“With the COVID-19 pandemic continuing its
devastating global impact, preparedness for the possibility of
future pandemics are of increasing importance for governments
worldwide. We look forward to providing information about TPOXX in
addressing a potential smallpox outbreak, which is far more lethal
than COVID-19,” said Dr. Hruby.
ABOUT SIGA TECHNOLOGIES, INC. and
TPOXX®
SIGA Technologies, Inc. is a commercial-stage
pharmaceutical company focused on the health security market.
Health security comprises countermeasures for biological, chemical,
radiological and nuclear attacks (biodefense market), vaccines and
therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat
and ST-246®, an orally administered and IV formulation antiviral
drug for the treatment of human smallpox disease caused by variola
virus. TPOXX® is a novel small-molecule drug and the US maintains a
stockpile of 1.7 million courses in the Strategic National
Stockpile under Project BioShield. The oral formulation of TPOXX®
was approved by the FDA for the treatment of smallpox in 2018. The
full label is here:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253.
In September 2018, SIGA signed a contract potentially worth more
than $600 million with BARDA for additional procurement and
development related to both oral and intravenous formulations of
TPOXX®. For more information about SIGA, please visit
www.siga.com.
About
Smallpox1
Smallpox is a contagious, disfiguring and often
deadly disease that has affected humans for thousands of years.
Naturally occurring smallpox was eradicated worldwide by 1980, the
result of an unprecedented global immunization campaign. Samples of
smallpox virus have been kept for research purposes. This has led
to concerns that smallpox could someday be used as a biological
warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine
vaccination for people at low risk of exposure to the smallpox
virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are subject to various known and unknown
risks and uncertainties, and SIGA cautions you that any
forward-looking information provided by or on behalf
of SIGA is not a guarantee of future performance. More
detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange
Commission, including SIGA's Annual Report on Form 10-K
for the year ended December 31, 2019, and in other documents
that SIGA has filed with
the SEC. SIGA urges investors and security holders
to read those documents free of charge at the SEC's web
site at http://www.sec.gov. Interested parties may also obtain
those documents free of charge from SIGA. Forward-looking
statements are current only as of the date on which such statements
were made, and except for our ongoing obligations under the
United States of America federal securities laws, we undertake
no obligation to update publicly any forward-looking statements
whether as a result of new information, future events, or
otherwise.
The information contained in this press release
does not necessarily reflect the position or the policy of the
Government and no official endorsement should be inferred.
Contacts:InvestorsDavid Carey
212-867-1768david.carey@finnpartners.com
MediaStephanie
Seiler206-713-0124stephanie.seiler@finnpartners.com
______________________________________
1
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Apr 2023 to Apr 2024